According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone;
- accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe;
- the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint;
- accordingly, defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects; and
- as a result, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
